RxDoctor Payments Data

Paul Szwejbka

Neurology · Fayetteville, NCNPI 1366447757

Payments from drug & device makers

$6,856in general payments, 2019–2025

Across 301 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$986
  • TG Therapeutics, Inc.$714
  • AstraZeneca$520
  • Eisai Inc.$344
  • Otsuka America Pharmaceutical, Inc.$276
  • Teva Pharmaceuticals USA, Inc.$264
  • plus $4K from 46 others

What the payments were for

  • Speaking & faculty fees$411%
  • Food & beverage$6,42594%
  • Education$3906%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,856 in reported general payments places this provider in the 65th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$698,667
Medicare patients
295
Services billed
19,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5022$325,022
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$199,531
Rebif RebidoseInterferon Beta-1a/Albumin11$113,266
Lamictal XrLamotrigine15$58,122
NuplazidPimavanserin Tartrate11$53,846
Nurtec OdtRimegepant Sulfate21$36,145
FycompaPerampanel29$35,681
Aimovig AutoinjectorErenumab-Aooe45$35,362
NourianzIstradefylline16$33,875
VimpatLacosamide16$29,502
BriviactBrivaracetam20$29,258
NuedextaDextromethorphan Hbr/Quinidine18$15,411
AptiomEslicarbazepine Acetate12$14,646
KeppraLevetiracetam11$8,481
Dimethyl Fumarate39$7,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra, Privigen$40$524,55334 claims
UCB, Inc.Vimpat, Briviact$225$58,76036 claims
Acadia Pharmaceuticals IncNuplazid$180$53,84611 claims
PfizerNurtec Odt$209$36,14521 claims
Eisai Inc.Fycompa$344$35,68129 claims
Kyowa Kirin, Inc.Nourianz$29$33,87516 claims
Avanir Pharmaceuticals, Inc.Nuedexta$82$15,41118 claims
Sunovion Pharmaceuticals Inc.Aptiom$163$14,64612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 566 neurology providers in North Carolina.

Other neurology in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →